Project description
A DNA vaccine platform against SARS-CoV-2
Accumulating genetic evidence on the new SARS-CoV-2 virus shows that its envelope and receptor binding domain only share 75 % homology with other human coronaviruses. This indicates that existing immunotherapies and vaccine candidates against other coronaviruses will probably not work against SARS-CoV-2. To generate and select the most potent candidates that protect against SARS-CoV-2 infection, the EU-funded OPENCORONA project will use a DNA vaccine platform. The most promising leads will initially be validated in animal models of coronavirus infection and then tested in a phase I clinical trial for safety in healthy volunteers.
Fields of science
Programme(s)
Funding Scheme
RIA - Research and Innovation action
Coordinator
17177 Stockholm
Sweden
See on map
Participants (6)
35390 Giessen
See on map
171 82 Solna
See on map
41012 Carpi Mo
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
864 23 Matfors
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
751 03 Uppsala
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
104 22 Stockholm
See on map